Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Granted US Patent for Lung Cancer Biomarkers

Premium

Vermillion said this week it has received a US patent covering serum protein biomarkers for lung cancer.

The patent, No. 8,014,952, entitled "Serum Biomarkers in Lung Cancer," describes 50 protein biomarkers that can be used to distinguish between patients with and without lung cancer and to determine the particular type of lung cancer.

"This patent highlights ongoing progress in expanding our intellectual property portfolio," Vermillion CEO Gail Page said in a statement. "Beyond our core focus areas of ovarian cancer and peripheral artery disease, we now have patents in lung cancer, breast cancer, and Alzheimer's disease. It is our goal to explore business opportunities to leverage this growing and valuable asset."

In addition to Vermillion, Hong Kong's Queen Elizabeth Hospital is listed as an assignee on the patent.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.